• May 2, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 17, 2017, in Las Vegas, Nev. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 4:00 p.m. ET (1:00 p.m. PT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visitingmore...
  • April 26, 2017
    ZAVENTEM, Belgium--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the company marketing authorization for Cytopoint (lokivetmab), the first monoclonal antibody (mAb) therapy approved in the European Union for veterinary use. Cytopoint is indicated to treat the clinical signs, including itching and inflammation, associated with atopic dermatitis in dogs of any age weighing 3 kilograms or more. Cytopoint targets andmore...
  • April 13, 2017
    PARSIPPANY, N.J. & TULLAMORE, Ireland--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) and Nexvet Biopharma plc (Nasdaq:NVET) today announced an agreement in which Zoetis, through a wholly owned subsidiary (“Zoetis Bidco”), will purchase Nexvet, an innovator in monoclonal antibody therapies for companion animals, for a purchase price of US$6.72 per share, representing an aggregate equity valuation of approximately US$85 million. The acquisition will strengthen Zoetis’ pipeline of solutions for chronicmore...
  • April 13, 2017
    PARSIPPANY, N.J. & TULLAMORE, Ireland--(BUSINESS WIRE)--COMPANY NAME: ZOETIS INC. HEADLINE: ZOETIS TO ACQUIRE NEXVET FOR US$85 MILLION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY RESTRICTED JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE 13 April 2017 ZOETIS TO ACQUIRE NEXVET FOR US$6.72 IN CASH PERmore...
  • April 5, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS), the leading global animal health company, today announced that music and television star Nick Lachey* is teaming up with the company to launch Your Animal Instinct , a program to help your dog put its best paw forward this spring. Your Animal Instinct aims to help pet owners understand when their dog’s itching may be due to an allergy-related skin condition – and what they can do about it.more...
  • March 31, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 4, 2017. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review first quarter 2017 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://more...
  • March 21, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Jefferies Animal Health Summit on Thursday, March 30, 2017, in New York, N.Y. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 9:30 a.m. ET. The presentation is not scheduled to be webcast. Investors and other interested parties will be able to access the presentation materials at http://investor.more...
  • February 17, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Cowen and Company 37th Annual Health Care Conference on March 6, 2017, in Boston, Mass. Clint Lewis, Executive Vice President and President, International Operations at Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 4:00 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of themore...
  • February 16, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the fourth quarter and full year 2016 and updated its guidance for the full year 2017. The company reported revenue of $1.3 billion for the fourth quarter of 2016, which was flat compared with the fourth quarter of 2015. Net income for the fourth quarter of 2016 was $154 million, or $0.31 per diluted share compared with $22 million and $0.04 per diluted share inmore...
  • February 15, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the company a license for Stronghold® Plus (selamectin/sarolaner), a topical combination of parasiticides that treats ticks, fleas, ear mites, lice and gastrointestinal nematodes and prevents heartworm disease in cats. Veterinarians across the European Union now have a treatment choice that leverages the benefits of sarolaner, a new innovation inmore...